Tonix Pharmaceuticals Holding Corp (TNXP)

1.95
0.00 (0.00)
NASDAQ : Health Care
Prev Close 1.95
Open 2.00
Day Low/High 1.92 / 2.01
52 Wk Low/High 1.84 / 8.95
Volume 204.88K
Avg Volume 443.60K
Exchange NASDAQ
Shares Outstanding 18.89M
Market Cap 37.78M
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Can You Catch These 6 Stocks Under $10 on Their Way Up?

Can You Catch These 6 Stocks Under $10 on Their Way Up?

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

6 Stocks Under $10 Making Big Moves Higher

6 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Programs Update

Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Programs Update

Key Clinical Results in Fibromyalgia and Post-Traumatic Stress Disorder (PTSD) to be Reported in 2016

Trade These 5 Breakout Stocks for Big Gains

Trade These 5 Breakout Stocks for Big Gains

These stocks look poised to break out and trade higher from current levels.

Tonix Pharmaceuticals Appoints Chief Financial Officer

Tonix Pharmaceuticals Appoints Chief Financial Officer

- Bradley J. Saenger Promoted Internally -

Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Trial Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Trial Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD)

Top-Line Results on Track to be Reported in the Second Quarter of 2016

Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Study Of TNX-201 In Episodic Tension-Type Headache

Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Study Of TNX-201 In Episodic Tension-Type Headache

Top-Line Results to be Reported in the First Quarter of 2016